{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T07:13:58Z","timestamp":1782026038662,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100001545","name":"Children's Tumor Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"DOI":"10.1007\/s10689-025-00520-5","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T07:16:50Z","timestamp":1765869410000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u201cIt\u2019s not any one thing, it\u2019s always all of them, all at the same time\u201d: quality of life in NF2-related schwannomatosis from patient and clinician perspectives"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8974-5896","authenticated-orcid":false,"given":"Sophia C.","family":"Carias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1324-7857","authenticated-orcid":false,"given":"Frank D.","family":"Buono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesel","family":"Von Imhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha M.","family":"Yelamanchili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-3392","authenticated-orcid":false,"given":"Kaleb H.","family":"Yohay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4064-6079","authenticated-orcid":false,"given":"P. Leia","family":"Nghiemphu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6981-1352","authenticated-orcid":false,"given":"Dusica","family":"Babovic-Vuksanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6109-6419","authenticated-orcid":false,"given":"Scott R.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4542-5227","authenticated-orcid":false,"given":"Vanessa L.","family":"Merker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"520_CR1","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.gim.2022.05.007","volume":"24","author":"SR Plotkin","year":"2022","unstructured":"Plotkin SR, Messiaen L, Legius E et al (2022) Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med 24:1967\u20131977","journal-title":"Genet Med"},{"key":"520_CR2","doi-asserted-by":"publisher","first-page":"098","DOI":"10.1055\/s-0036-1579766","volume":"05","author":"J Kresak","year":"2016","unstructured":"Kresak J, Walsh M (2016) Neurofibromatosis: A review of NF1, NF2, and Schwannomatosis. J Pediatr Genet 05:098\u2013104","journal-title":"J Pediatr Genet"},{"key":"520_CR3","unstructured":"Evans DG (1993) NF2-Related Schwannomatosis. GeneReviews\u00ae"},{"key":"520_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11060-013-1195-2","volume":"114","author":"A-M Vranceanu","year":"2013","unstructured":"Vranceanu A-M, Merker VL, Park E, Plotkin SR (2013) Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol 114:257\u2013262","journal-title":"J Neurooncol"},{"key":"520_CR5","unstructured":"Mayo NE (2015) ISOQOL Dictionary of Quality of Life and Health Outcomes Measurement. International Society for Quality of Life Research (ISOQOL)"},{"key":"520_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1177\/0194599815573002","volume":"153","author":"MK Cosetti","year":"2015","unstructured":"Cosetti MK, Golfinos JG, Roland JT (2015) Quality of life (QoL) assessment in patients with neurofibromatosis type 2 (NF2). Otolaryngol-Head Neck Surg 153:599\u2013605","journal-title":"Otolaryngol-Head Neck Surg"},{"key":"520_CR7","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/MAO.0000000000001019","volume":"37","author":"VL Merker","year":"2016","unstructured":"Merker VL, Bergner AL, Vranceanu A-M, Muzikansky A, Slattery W, Plotkin SR (2016) Health-related quality of life of individuals with neurofibromatosis type 2: results from the NF2 natural history study. Otol Neurotol 37:574\u2013579","journal-title":"Otol Neurotol"},{"key":"520_CR8","doi-asserted-by":"publisher","first-page":"i141","DOI":"10.1093\/noajnl\/vdaa003","volume":"2","author":"G Hamoy-Jimenez","year":"2020","unstructured":"Hamoy-Jimenez G, Kim R, Suppiah S, Zadeh G, Bril V, Barnett C (2020) Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. Neuro Oncol Adv 2:i141\u2013i149","journal-title":"Neuro Oncol Adv"},{"key":"520_CR9","doi-asserted-by":"publisher","first-page":"104279","DOI":"10.1016\/j.bas.2025.104279","volume":"5","author":"AC Lawson McLean","year":"2025","unstructured":"Lawson McLean AC, Rosahl SK, Lawson McLean A, Fehringer P, Freier A, L\u00f6schner D, Kamp MA, Senft C, Demetriades AK (2025) Quality of life assessment in schwannomatosis \u2013 a systematic review. Brain Spine 5:104279","journal-title":"Brain Spine"},{"key":"520_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1749-4486.2010.02176.x","volume":"35","author":"WJ Neary","year":"2010","unstructured":"Neary WJ, Hillier VF, Flute T, Stephens SDG, Ramsden RT, Evans DGR (2010) The relationship between patients\u2019 perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol 35:291\u2013299","journal-title":"Clin Otolaryngol"},{"key":"520_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1265\/ehpm.24-00158","volume":"29","author":"T Yamauchi","year":"2024","unstructured":"Yamauchi T, Suka M (2024) Quality of life and neurological symptoms in patients with neurofibromatosis type 2: a national database study in Japan. Environ Health Prev Med 29:44\u201344","journal-title":"Environ Health Prev Med"},{"key":"520_CR12","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1212\/CPJ.0000000000000648","volume":"9","author":"A Shukla","year":"2019","unstructured":"Shukla A, Hsu F-C, Slobogean B, Langmead S, Lu Y, Blakeley JO, Strowd RE (2019) Association between patient-reported outcomes and objective disease indices in people with NF2. Neurol Clin Pract 9:322\u2013329","journal-title":"Neurol Clin Pract"},{"key":"520_CR13","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/pon.5099","volume":"28","author":"LM Quarmby","year":"2019","unstructured":"Quarmby LM, Dalton LJ, Woolrich RA, Clarke R, Emmanouil B, Patel S, Rands G, Parry A, Halliday D (2019) Screening and intervening: psychological distress in neurofibromatosis type 2 (NF2). Psychooncology 28:1583\u20131587","journal-title":"Psychooncology"},{"key":"520_CR14","doi-asserted-by":"publisher","first-page":"6934","DOI":"10.1038\/s41598-024-57401-7","volume":"14","author":"A Freier","year":"2024","unstructured":"Freier A, Lawson McLean AC, Loeschner D, Rosahl SK, Kruse J (2024) The impact of mental health on health-related quality of life in patients with NF2-related Schwannomatosis. Sci Rep 14:6934","journal-title":"Sci Rep"},{"key":"520_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1080\/16513860601113809","volume":"4","author":"WJ Neary","year":"2006","unstructured":"Neary WJ, Stephens D, Ramsden RT, Evans G (2006) Psychosocial effects of neurofibromatosis type 2 (part 1): general effects. Audiol Med 4:202\u2013210","journal-title":"Audiol Med"},{"key":"520_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/13548506.2010.516363","volume":"16","author":"CM Patel","year":"2011","unstructured":"Patel CM, Ferner R, Grunfeld EA (2011) A qualitative study of the impact of living with neurofibromatosis type 2. Psychol Health Med 16:19\u201328","journal-title":"Psychol Health Med"},{"key":"520_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1055\/s-0032-1301396","volume":"73","author":"R Hornigold","year":"2012","unstructured":"Hornigold R, Golding J, Leschziner G, Obholzer R, Gleeson M, Thomas N, Walsh D, Saeed S, Ferner R (2012) The NFTI-QOL: a disease-specific quality of life questionnaire for neurofibromatosis 2. J Neurol Surg B 73:104\u2013111","journal-title":"J Neurol Surg B"},{"key":"520_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11060-015-1725-1","volume":"122","author":"A-M Vranceanu","year":"2015","unstructured":"Vranceanu A-M, Merker VL, Park ER, Plotkin SR (2015) Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature. J Neurooncol 122:219\u2013228","journal-title":"J Neurooncol"},{"key":"520_CR19","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1056\/NEJMoa2400985","volume":"390","author":"SR Plotkin","year":"2024","unstructured":"Plotkin SR, Yohay KH, Nghiemphu PL, Dinh CT, Babovic-Vuksanovic D, Merker VL, Bakker A, Fell G, Trippa L, Blakeley JO (2024) Brigatinib in NF2-related schwannomatosis with progressive tumors. N Engl J Med 390:2284\u20132294","journal-title":"N Engl J Med"},{"key":"520_CR20","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker DM, Lamoureux RE, Stokes J, Litcher-Kelly L, Galipeau N, Yaworsky A, Solomon J, Shields AL (2018) Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health 21:839\u2013842","journal-title":"Value Health"},{"key":"520_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1471-2288-13-117","volume":"13","author":"NK Gale","year":"2013","unstructured":"Gale NK, Heath G, Cameron E, Rashid S, Redwood S (2013) Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol 13:117","journal-title":"BMC Med Res Methodol"},{"key":"520_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J (2007) Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 19:349\u2013357","journal-title":"Int J Qual Health Care"},{"key":"520_CR23","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00415-014-7303-1","volume":"261","author":"RE Ferner","year":"2014","unstructured":"Ferner RE, Shaw A, Evans DG et al (2014) Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. J Neurol 261:963\u2013969","journal-title":"J Neurol"},{"key":"520_CR24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/0001-8791(80)90056-1","volume":"16","author":"DE Super","year":"1980","unstructured":"Super DE (1980) A life-span, life-space approach to career development. J Vocat Behav 16:282\u2013298","journal-title":"J Vocat Behav"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-025-00520-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-025-00520-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-025-00520-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T20:02:15Z","timestamp":1765915335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-025-00520-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["520"],"URL":"https:\/\/doi.org\/10.1007\/s10689-025-00520-5","relation":{},"ISSN":["1573-7292"],"issn-type":[{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SCC, FDB, LVI, SMY, HC, and PLN have no relevant financial or non-financial interests to disclose. KHY is a consultant for Alexion Pharmaceuticals and a member of the scientific advisory board of Infixion. DBV is a member of the advisory board of Alexion Pharmaceuticals and SpringWorks Therapeutics. SRP is a consultant for Akouos, co-founder and consultant of NF Therapeutics and NFlection Therapeutics, and a member of the scientific advisory board of SonALAsense. VLM has received consulting income from Alexion Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All study procedures were reviewed and approved by the Dana Farber\/Harvard Cancer Center Institutional Review Board under protocol 19-828 and the Mass General Brigham Institutional Review Board under protocol 2023P003305.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"4"}}